Acelyrin has offered a more detailed look at positive Phase 2 data for its thyroid eye disease drug candidate as it tees up ...

Orbis Medicines raises €90M Series A led by NEA for macrocycle drug development, with backing from Eli Lilly, Cormorant Asset ...

Revance Therapeutics’ contract dispute with a Swiss partner has caused hiccups in its plan to be acquired by Crown ...

San Diego-based Velia Therapeutics, which was working on so-called microproteins, is in the process of winding down about two ...

WuXi Biologics’ subsidiary WuXi Vaccines is divesting a manufacturing facility in Dundalk, Ireland, to Merck for $500 million, roughly a week after WuXi AppTec also announced it's shrinking its ...

I-Mab halts CD73 program to focus on givastomig, General Proximity emerges with $16M for undruggable proteins, PBS Biotech raises $17M, Citius explores sale ...

Oculis' OCS-05 succeeds in Phase 2 trial for acute optic neuritis, showing improved vision and retinal measures. FDA clears ...

Iambic Therapeutics has hired a CFO, poaching an executive who helped engineer the first big merger in the AI-driven biotech ...

Neumora's depression drug fails Phase 3, Pfizer exits Sangamo hemophilia A gene therapy partnership, and biotech sees surge in megarounds with 96 nine-figure financings in 2024.

A Florida-based car dealer has joined mounting litigation against Eli Lilly, Novo Nordisk and Sanofi over what it calls the “exorbitant” price of insulin.

Eli Lilly has asked to intervene in litigation between a compounding pharmacy trade group and the FDA over the agency’s ...

Novo Nordisk is continuing its citizen petition crusade at the FDA, this time aiming to stop the compounding of Victoza, its ...